GSK announced that the European Medicine Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended for use a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by bacterial groups A, C, W, and Y. Marketing authorization in EU expected by November 2024. Over 6 million doses of GSK‘s MenACWY vaccine have been distributed to European countries since 2017 to help protect against invasive meningococcal disease
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK reached two confidential settlements in Zantac cases filed in California
- GSK announces topline data on co-administration of Arexvy, Shingrix
- GSK announces MHLW accepted for review a NDA for Blenrep
- iTeos Therapeutics announces follow-up interim data from GALAXIES Lung-201
- GSK Pharma put volume heavy and directionally bearish
